Core Insights - The article highlights the significant benefits of Semaglutide for patients with type 2 diabetes and peripheral artery disease (PAD), emphasizing its ability to improve walking ability and quality of life without being affected by individual patient characteristics [8][19][20]. Group 1: Research Findings - Semaglutide shows a notable improvement in maximum walking distance (MWD) and pain-free walking distance (PFWD) for patients with symptomatic PAD, regardless of diabetes duration, BMI, or blood sugar control [10][12][13][14]. - The STRIDE trial included 792 patients with symptomatic PAD, demonstrating that all patient subgroups benefited from Semaglutide treatment [9][10]. - The study revealed that the improvement in walking ability was independent of weight loss and blood sugar control, suggesting a novel mechanism of action for Semaglutide [17][18]. Group 2: Clinical Implications - The findings indicate that Semaglutide can serve as a comprehensive treatment option for PAD in type 2 diabetes patients, enhancing lower limb blood circulation and functional capacity [20][21]. - The safety profile of Semaglutide was comparable to that of the placebo group, with no significant increase in adverse events, including hypoglycemia [18][19]. - This research opens new avenues for treating the challenging combination of diabetes and PAD, providing valuable clinical guidance [21].

Core Viewpoint - Semaglutide, a GLP-1 receptor agonist, shows significant benefits for patients with type 2 diabetes and peripheral artery disease (PAD), improving both walking distance and quality of life, beyond its glucose-lowering effects [3][10][13]. Research Objectives - The study aims to analyze the efficacy of semaglutide in improving functionality in type 2 diabetes patients with PAD, focusing on whether the effects are consistent across different clinical characteristics [5]. Research Methodology - The STRIDE trial included 792 patients with symptomatic PAD and type 2 diabetes, using a randomized, double-blind design over 52 weeks, comparing semaglutide treatment to a placebo [7]. Key Assessment Indicators - The primary endpoint was the improvement in maximum walking distance (MWD) after 52 weeks, with supplementary assessments on pain-free walking distance (PFWD) [9]. Research Results - Semaglutide significantly improved both MWD and PFWD across various patient characteristics, indicating a stable efficacy regardless of factors such as diabetes duration, body mass index (BMI), and blood glucose control [10][12]. - The average weight loss was 4.09 kg, and HbA1c levels decreased by 0.99%, but the benefits for PAD may operate through independent mechanisms [11][12]. Safety Profile - The safety of semaglutide was confirmed, with adverse event rates comparable to the placebo group, and no new safety concerns were identified [13]. Conclusion - Semaglutide is a promising treatment option for type 2 diabetes patients with PAD, demonstrating efficacy beyond traditional mechanisms, including improvements in endothelial function and microcirculation [16].